*Publication*

Kaur S, *et al.* Role of CD47 in triple negative breast cancer. FASEB J. 2015 April;29(1 Supplement); Abstract 890.5. [*http://www.fasebj.org/content/29/1_Supplement/890.5*]

*Intellectual Property:* HHS Reference No. E–263–2014/0—US Application No. 62/062,675 filed October 10, 2014.

*Related Technologies*

- HHS Reference No. E–227–2006/5—US Patent 8,236,313 issued August 7, 2012; US Patent 8,557,788 issued October 15, 2013; US Patent 8,865,672 issued October 21, 2014.
- HHS Reference No. E–153–2008/0—US Patent No. 8,951,527 issued February 10, 2015.
- HHS Reference No. E–086–2012/1—US Patent Application No. 61/735,701 filed December 11, 2012.
- HHS Reference No. E–296–2011/0—Application PCT/US2014/025989 filed March 13, 2014.

*Licensing Contact:* Jaime M. Greene; 301–435–5559; *jaime.greene@mail.nih.gov.*

*Collaborative Research Opportunity:* The National Cancer Institute, Center for Cancer Research, Laboratory of Pathology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize methods to differentiate cancer stem cells. For collaboration opportunities, please contact John D. Hewes, Ph.D. at *hewesj@mail.nih.gov.*

**Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2**

*Description of Technology:* Herpes simplex viral infections, including herpes simplex virus type 1 (HSV–1) and type 2 (HSV–2), are exceptionally common worldwide. These viruses establish lifelong persistent infections with cycles of lytic reactivation to produce recurrent diseases including oral and genital lesions, herpetic keratitis/blindness, congenital-developmental syndromes, and viral encephalitis. Infection with HSV–2 increases the rate of human immunodeficiency virus (HIV) transmission in coinfected individuals. DNA replication inhibitors are typically used to treat herpesvirus infections. However, these compounds do not completely suppress infection, viral shedding, reactivation from latency, and the inflammation that contributes to diseases such as keratitis. An unmet need continues to exist for methods of preventing or treating herpesviral infections. The application claims methods of preventing or treating herpesviral infection of a host, comprising administering to the host an effective amount of an inhibitor of the EZH1/2 histone methyltransferase activities. The application is not limited to herpes simplex virus but rather is applicable to other viral infections as well.

*Potential Commercial Applications*

- HSV therapeutics
- HSV vaccines

*Competitive Advantages*

- Low-cost production
- Ease of synthesis

*Development Stage*

- In vitro data available
- In vivo data available (animal)

*Inventors: Thomas* M. Kristie and Jesse H. Arbuckle (NIAID)

*Intellectual Property:* HHS Reference E–141–2015/0—US Provisional Patent Application 62/155,704 filed 01 May 2015

*Related Technologies*

- HHS Reference E–275–2008/0—US Patent Number 8,916,596 issued 23 Dec 2014; US Application No. 14/543,321 filed 17 Nov 2014; PCT Application No. PCT/US2009/051557 filed 23 Jul 2009
- HHS Reference E–184–2010/0—US Patent Number 8,871,789 issued 28 Oct 2014; PCT Application No. PCT/US2011/044835 filed 21 Jul 2011

*Licensing Contact:* Peter Soukas; 301–435–4646; *ps193c@nih.gov*

Dated: August 7, 2015.

**Richard U. Rodriguez,**

*Acting Director, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2015–19912 Filed 8–12–15; 8:45 am]

**BILLING CODE 4140–01–P**

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDDK.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Board of Scientific Counselors, NIDDK.

*Date:* September 10–11, 2015.

Open: September 10, 2015, 8:00 a.m. to 8:20 a.m.

*Agenda:* Introductions and Overview.

*Place:* National Institutes of Health, Building 5, Room 127, 5 Memorial Drive, Bethesda, MD 20892.

Closed: September 10, 2015, 8:20 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate personal qualifications and performance, and competence of individual investigators.

*Place:* National Institutes of Health, Building 5, Room 127, 5 Memorial Drive, Bethesda, MD 20892.

Closed: September 11, 2015, 8:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate personal qualifications and performance, and competence of individual investigators.

*Place:* National Institutes of Health, Building 5, Room 127, 5 Memorial Drive, Bethesda, MD 20892.

*Contact Person:* Michael W. Krause, Ph.D., Scientific Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Building 5, Room B104, Bethesda, MD 20892–1818, (301) 402–4633, *mwkrause@helix.nih.gov.*

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: August 10, 2015.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015–19940 Filed 8–12–15; 8:45 am]

**BILLING CODE 4140–01–P**